My laboratory has focused on understanding of stem cell fate changes. We have been interested in using pluripotent stem cells as research tools for studying human hepatogenesis and pathogenesis of liver diseases. We have generated a large panel of human induced pluripotent stem cell (iPSC) lines from various sources (of both healthy- and disease- tissues) including primary hepatocytes, bone marrow stem cells, blood cells, keratinocytes, fibroblasts and tumor cells. In addition, we have successfully differentiated these iPSCs into endoderm as well as early and late stage hepatic cells by a step wise hepatic specification protocol. We have shown the comprehensive functionality of these iPSC derived liver cells using both in vitro and in vivo assays. Recently, our iPSC generation and hepatic differentiation as well as gene targeting technologies have been successfully utilized in liver disease modelling, pathogenesis study, drug discovery, and cell therapy. We are currently committed to the discovery and development of novel therapeutic approaches to liver disease prevention and treatment using this patient specific iPSC technology.
- Jang YY, Collector MI, Baylin SB, Diehl AM, Sharkis SJ. Hematopoietic stem cells convert into liver cells within days without fusion. Nature Cell Biology 2004; 6: 532-9.
- Jang YY (Corresponding author), Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood. 2007; 110: 3056-3063 (Commented in Blood, 2007: 110: 2783-2784).
- Liu H, Ye Z, Kim Y, Sharkis S, Jang YY (Corresponding author). Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology 2010, 51(5):1810-1819.
- Liu H, Kim Y, Sharkis S, Marchionni L and Jang YY (Corresponding author). In vivo Liver Regeneration Potential of Human Induced Pluripotent Stem Cells from Diverse Origins. Science Transl Med 2011; 3(82): 82ra39.
- Choi SM, Liu H, Chaudhari P, Kim Y, Cheng L, Feng J, Sharkis, S, Ye Z and Jang YY (Corresponding author). Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood, 2011; 118:(7): 1801-5.
- Ye Z, Liu CF, Jang YY (Corresponding author). Hematopoietic cells as sources for patient-specific iPSCs and disease modeling. Cell Cycle. 2011 Sep 1;10(17):2840-4.
- Choi SM, Kim Y, Liu H, Chaudhari P, Ye Z and Jang YY (Corresponding author). Liver Engraftment Potential of Hepatic Cells derived from Patient Specific Induced Pluripotent Stem Cells. Cell Cycle 2011; 10(15): 2423-7.
- Sharkis SJ, Jones RJ, Civin C, Jang YY (Corresponding author). Pluripotent stem cell-based cancer therapy: promise and challenges. Science Transl Med. 2012;4(127):127ps9.
- Chaudhari P, Ye Z, Jang YY (Corresponding author). Roles of Reactive Oxygen Species in the Fate of Stem Cells. Antioxid Redox Signal. 2012 Nov 19. [Epub ahead of print]
- Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, Liu JO, Deng C, Ye Z, Jang YY (Corresponding author). Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology. 2013;57(6):2458-68.